Novo Nordisk stock enters November with obesity data catalyst

Novo Nordisk enters the next reporting week with two developments focused on its obesity and diabetes portfolio. On October 29, the company said it would present findings across 26 abstracts at ObesityWeek 2026 in Washington, D.C., from November 14 to 17. The announcement was carried by PR Newswire.

Clinical agenda moves into focus

The planned program covers investigational CagriSema, real-world treatment experience with oral and injectable Wegovy, and investigational semaglutide research in children aged six to under 12. Novo said the CagriSema schedule includes primary results from the lower-dose REDEFINE 9 study and additional analyses from REDEFINE 1.

CagriSema remains investigational and is not approved in the United States or elsewhere. That limits the immediate commercial conclusion investors can draw from the November agenda, but the presentations may add detail on dosing, patient experience and treatment outcomes across the obesity portfolio.

Weekly insulin approval broadens reach

On October 23, the US Food and Drug Administration approved Awiqli, a once-weekly long-acting basal insulin, for children aged 10 and older with type 2 diabetes. The approval reduces the scheduled frequency of basal injections from seven per week to one and extends the product's approved population beyond adults.

The regulatory decision is separate from Novo's obesity pipeline. It nevertheless gives the company another commercial product milestone as investors assess the balance between established medicines, new indications and investigational treatments.

The real-time quote of Novo Nordisk stock was 35.76 euros on Lang & Schwarz at 10:44 CEST on Saturday, October 31.

The Euro Stoxx 50 market provides the broader regional backdrop for European healthcare shares.

More news and analyses on Novo Nordisk stock